H Lundbeck A/S
CSE:HLUN A

Watchlist Manager
H Lundbeck A/S Logo
H Lundbeck A/S
CSE:HLUN A
Watchlist
Price: 33.6 DKK 1.97%
Market Cap: 33.5B DKK
Have any thoughts about
H Lundbeck A/S?
Write Note

H Lundbeck A/S
Cash Paid for Dividends

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

H Lundbeck A/S
Cash Paid for Dividends Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash Paid for Dividends CAGR 3Y CAGR 5Y CAGR 10Y
H Lundbeck A/S
CSE:HLUN A
Cash Paid for Dividends
-kr576m
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Novo Nordisk A/S
CSE:NOVO B
Cash Paid for Dividends
-kr44.1B
CAGR 3-Years
-27%
CAGR 5-Years
-18%
CAGR 10-Years
-14%
ALK-Abello A/S
CSE:ALK B
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Stenocare A/S
CSE:STENO
Cash Paid for Dividends
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

H Lundbeck A/S
Glance View

Market Cap
33.3B DKK
Industry
Pharmaceuticals

Founded in 1915 by Hans Lundbeck, H. Lundbeck A/S has grown from a small trading company into a notable player within the pharmaceutical industry, specializing in the treatment of brain diseases. Over the decades, the company honed its focus on neuroscience, particularly targeting mental health disorders. This specialization has allowed Lundbeck to establish a strong presence in the therapeutic areas of depression, schizophrenia, Alzheimer's, and Parkinson's diseases. The company's operations are grounded in a rigorous commitment to research and development, constantly seeking breakthroughs that can transform mental health treatment. A significant portion of its revenue is channeled back into R&D to maintain its pipeline of innovative pharmaceuticals, ensuring a future driven by new drug discoveries that align with patient needs. Lundbeck’s revenue streams primarily stem from its portfolio of prescription medicines, marketed globally across numerous countries. The company capitalizes particularly on a few blockbuster drugs, forming strategic alliances and partnerships to expand its reach and efficacy. Through a robust distribution network, Lundbeck effectively channels its products from manufacturing through to consumers, including hospitals and pharmacies. Moreover, the company benefits from strategic collaborations with other pharmaceutical giants, enhancing its footprint in competitive markets. By continually investing in cutting-edge research and leveraging strategic partnerships, Lundbeck maintains its mission of delivering effective central nervous system therapies, ensuring a sustainable growth trajectory.

HLUN A Intrinsic Value
65.73 DKK
Undervaluation 49%
Intrinsic Value
Price

See Also

What is H Lundbeck A/S's Cash Paid for Dividends?
Cash Paid for Dividends
-576m DKK

Based on the financial report for Dec 31, 2023, H Lundbeck A/S's Cash Paid for Dividends amounts to -576m DKK.

What is H Lundbeck A/S's Cash Paid for Dividends growth rate?
Cash Paid for Dividends CAGR 3Y
11%

Over the last year, the Cash Paid for Dividends growth was -45%. The average annual Cash Paid for Dividends growth rates for H Lundbeck A/S have been 11% over the past three years .

Back to Top